A polyclonal antibody directed against csGRP78 has been shown to induce apoptosis in melanoma (A375) and prostate cancer cells (1-LN, DU145) through the up-regulation of p53, inhibition of NF-kappa B1 and NF-kappa B2 activation, and suppression of Ras/MAPK and PI3K/Akt signaling [27, 42, 43]. The gene discussed is TP53; the disease is prostate cancer.